Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - October 2013


SMi - Diabetes: Secondary Complications, Regulation and Innovation

01 Oct 2013 - 02 Oct 2013 - London, UK



Bookmark and Share


Join your peers at the only conference dedicated to the leading causes of mortality and morbidity in diabetes, this autumn, in London. Our distinguished faculty unite the fields of pharmacology, nanotechnology and clinical medicine to target atherosclerosis, endothelial inflammation and end-stage renal disease. 

SMi's unique program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy.  

“This conference is an excellent one stop shop to up-skill on current issues in diabetes therapy. I’m happy to chair what will no doubt be a very stimulating session.” – Phil Ambery, Medical Director, GlaxoSmithKline

Key Reasons to Attend:

Receive clinical updates on novel GLP1 receptor agonists, and SLGT2 and DPP-4 inhibitors

Utilise biomarkers and imaging for the development of novel therapies for diabetes

Discuss new therapeutic targets to reduce hypertension, hyperkalaemia and endothelial inflammation in diabetes

Remain abreast of new EU and FDA guidelines on clinical trials on risk-benefit assessment

Capitalise on the effects of targeting RAAS, CCN2 and CCN3 inhibitors

Review clinical results from the DEMAND study

Key Speakers Include: 

James F. List, Vice President and Full Development Lead, Dapagliflozin, Bristol-Myers Squibb

John Wilding, Professor of Medicine & Honorary Consultant Physician, Head of Department of Obesity and Endocrinology, University of Liverpool Hospital

Martin Siman, Director, Design and Interpretation Centre of Excellence, AstraZeneca

Philip Ambery, Director, Clinical Development, GlaxoSmithKline

Sandra Souza, Team Lead, Molecular Biomarkers, PPDM , Merck Sharp & Dohme 

Diabetes: Secondary Complications, Regulation and Innovation, promises to be a unique platform for networking, problem solving and learning from timely case studies. This really is a unique event not to be missed.

Book online at www.smi-online.co.uk/goto/2013diabetes-conference28.asp

Contact John Collins: Email: jcollins@smi-online.co.uk Tel: +44 (0)207 827 6734




Further information
Scientific News
Targeting Fat to Treat Cancer
Researchers develop novel cancer treatment that halts fat synthesis in cells, stunting tumors.
NIH Study Finds Link Between Depression, Gestational Diabetes
Researchers at NIH have discovered that the depression in early pregnancy doubles risk for gestational diabetes, and gestational diabetes increases risk for postpartum depression.
Gut Pathogens Thrive on Body's Tissue-Repair Mechanism
Researcher have discovered that harm caused by pathogens in the intestinal tract benefit from immune system response to damaged intestinal lining.
Cancer's Taste for Fat
Researchers discovered signalling pathway for fat burning is disrupted in certain cancers.
‘Tracking Bugs’ Reveal Secret of Cancer Cell Metabolism
Unexpected finding shows instead of throwing away valuable nutrients, the cells squeeze out every last drop of energy.
Ginger Nano-Lipid Particles May Improve Cancer Treatment
Edible ginger-derived nano-lipids show promise for effectively targeting and delivering chemotherapeutic drugs used to treat colon cancer.
Genetic Diversity of Enzymes Alters Metabolic Individuality
ToMMo scientists have shown that genetic polymorphisms, structural location of mutation and effect for phenotype correlate with each other.
Absolute Quantification of Mitochondrial Metabolites
Scientists have developed a method to quickly isolate and systematically measure metabolite concentrations within mitochondria.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
Demonstrating LNP Delivery of CRISPR Components
Intellia has presented data demonstrating in vivo gene editing ising liquid nanoparticles (LNPs) to deliver CRISPR/Cas9.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!